oncliveMay 141 min read

ASCO 2026: All Eyes Are on Daraxonrasib and a Wave of Novel Targeted Therapies in GI Malignancies

Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

oncliveMay 141 min read

Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.